Simple objective detection of human Lyme disease infection using immuno-PCR and a single recombinant hybrid antigen. Micah D. Halpern, Claudia R. Molins, Martin Schriefer and Mollie W. Jewett http://cdli.asm.org/content/early/2014/06/03/CVI.00245-14 Per the following CDC/University of Florida study it appears that Lyme disease testing is no better than a coin toss. Our current 2-tier Lyme disease analysis has a sensitivity of 59%. Faulty diagnostic tests have led to the disability of tens of thousands of Lyme patients through misdiagnosis and delayed treatment. Late stage Lyme disease does not respond well to short courses of antibiotics leaving these patients with the dilemma and financial burden of finding a way to treat beyond the IDSA’s one-size-fits-all treatment guideline. It is time to recognize that serodiagnostics for Lyme disease is inherently flawed and should be scrapped for testing capable of measuring treatment failure or success.